Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 4INTERVENTIONAL

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

A Longitudinal, Open-label, Multi-center Study to Explore the Relationship Between Signs, Symptoms, Molecular and Imaging Biomarkers in Participants With Dry Eye Disease Following Anti-inflammatory Treatment

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study aims to evaluate the performance of biomarkers and their responsiveness to standard-of-care treatments (Vevye® or Xiidra®), in participants with dry eye disease (DED) compared to healthy volunteers (control participants).

Who May Be Eligible (Plain English)

Who May Qualify: A. Inclusion Criteria for Participants with DED: - The participant reported dry eye-related ocular symptoms for at least 6 months before the screening visit - The participant must have either used lubricant eye drops regularly OR had the desire to use lubricant eye drops in the past 3 months - Participant must be classified as having moderate/severe DED - The participant is deemed by the physician to require a prescription medication for DED (e.g., cyclosporin A or lifitegrast) B. Inclusion Criteria for Healthy Volunteers: \- The participant does not have overt clinical signs of DED in either eye Who Should NOT Join This Trial: - Intraocular pressure (IOP) \>21.00 millimeters of mercury (mmHg) in either eye - Acute allergic conjunctivitis in either eye within 3 months prior to screening - Use of contact lenses within 30 days prior to screening - Punctal plugs within 3 months prior to screening or any history of punctal cauterization or occlusion by an approach different from punctal plugs - Use of ocular anti-inflammatory agents or ocular immunosuppressive agents within 3 months prior to screening - Any intraocular injections (e.g., intravitreal \[IVT\] anti-vascular endothelial growth factor \[VEGF\]) within 3 months prior to screening, or such injections planned for within the study period - Any intraocular immunosuppressive implants within 12 months prior to screening - Any history of isotretinoin use within 12 months prior to screening - Uncontrolled ocular or systemic disease Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: A. Inclusion Criteria for Participants with DED: * The participant reported dry eye-related ocular symptoms for at least 6 months before the screening visit * The participant must have either used lubricant eye drops regularly OR had the desire to use lubricant eye drops in the past 3 months * Participant must be classified as having moderate/severe DED * The participant is deemed by the physician to require a prescription medication for DED (e.g., cyclosporin A or lifitegrast) B. Inclusion Criteria for Healthy Volunteers: \- The participant does not have overt clinical signs of DED in either eye Exclusion Criteria: * Intraocular pressure (IOP) \>21.00 millimeters of mercury (mmHg) in either eye * Acute allergic conjunctivitis in either eye within 3 months prior to screening * Use of contact lenses within 30 days prior to screening * Punctal plugs within 3 months prior to screening or any history of punctal cauterization or occlusion by an approach different from punctal plugs * Use of ocular anti-inflammatory agents or ocular immunosuppressive agents within 3 months prior to screening * Any intraocular injections (e.g., intravitreal \[IVT\] anti-vascular endothelial growth factor \[VEGF\]) within 3 months prior to screening, or such injections planned for within the study period * Any intraocular immunosuppressive implants within 12 months prior to screening * Any history of isotretinoin use within 12 months prior to screening * Uncontrolled ocular or systemic disease

Treatments Being Tested

DRUG

Vevye®

Participants will receive Vevye® (0.1% cyclosporine ophthalmic solution) as per the schedule described in the treatment arm.

DRUG

Xiidra®

Participants will receive Xiidra® (5% lifitegrast ophthalmic solution) as per the schedule described in the treatment arm.

Locations (5)

Butchertown Clinical Trials
Louisville, Kentucky, United States
Andover Eye Associates
Andover, Massachusetts, United States
Oculus Research
Garner, North Carolina, United States
Total Eyecare, P.A.
Memphis, Tennessee, United States
Piedmont Eye Center
Lynchburg, Virginia, United States